Louis Lange Sells 28,186 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director Louis Lange sold 28,186 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.41, for a total value of $828,950.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

NewAmsterdam Pharma Stock Up 1.6%

NAMS stock traded up $0.50 during midday trading on Tuesday, reaching $31.27. 1,016,199 shares of the company’s stock traded hands, compared to its average volume of 840,101. The firm’s fifty day moving average price is $33.41 and its 200-day moving average price is $33.36. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00. The company has a market cap of $3.60 billion, a price-to-earnings ratio of -18.08 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. Analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC raised its holdings in shares of NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares during the period. Wells Fargo & Company MN increased its position in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the last quarter. Mather Group LLC. bought a new stake in shares of NewAmsterdam Pharma in the third quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of NewAmsterdam Pharma during the 3rd quarter valued at $30,000. Finally, Navalign LLC bought a new position in shares of NewAmsterdam Pharma during the 4th quarter worth $46,000. 89.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NAMS shares. Royal Bank Of Canada raised their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Leerink Partners reissued an “outperform” rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Needham & Company LLC lifted their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, Stifel Nicolaus upped their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $47.10.

More NewAmsterdam Pharma News

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: Several sell‑side firms have raised ratings and targets (Needham raised its target to $48, HC Wainwright upgraded to strong‑buy, RBC lifted its target to $47) and the consensus remains a “Moderate Buy” with an average target near $47, supporting upside expectations.
• Positive Sentiment: Large institutional positions and recent accumulation (Capital World Investors, Jennison, Duquesne and others increased stakes) signal continuing institutional confidence and provide potential buying support under the stock.
• Neutral Sentiment: Recent profile/coverage updates (e.g., Barron’s stock page) provide visibility but do not contain new material clinical or financial news likely to immediately change fundamentals. Barron’s stock page
• Negative Sentiment: Large, repeated insider sales by CFO/insider Johannes Jacob Piete Kastelein (multiple trades on March 5–9–6 totaling several hundred thousand shares and reducing his stake by roughly ~57–60%) are material — such concentrated selling can pressure the stock and raise investor concern about insider liquidity needs or sentiment. InsiderTrades: Kastelein sales SEC filing
• Negative Sentiment: Director Louis G. Lange sold 28,186 shares (March 6), another disclosed insider sale that adds to the net insider selling narrative. SEC filing
• Negative Sentiment: Recent quarterly results (Feb. 18) showed an EPS miss and very limited revenue, with negative margins — underlying fundamentals remain loss‑making, which keeps the stock sensitive to sentiment and execution risk.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.